1. Home
  2. News
  3. Vireo Growth Inc
  4. Vireo Growth Inc. Announces First Quarter 2025 Results
Vireo Growth Inc news

Investor announcements, newest first.

Close
Company news
Vireo Growth Inc
May 9, 2025 at 11:00 AM UTC
Original
ELI5

Vireo Growth Inc. Announces First Quarter 2025 Results

– Q1 revenue of $24.5 million increased 1.9% year-over-year, in line with expectations for Vireo’s established markets –

– Merger Transactions expected to begin closing in Q2 and further strengthen profitability profile –

MINNEAPOLIS, May 09, 2025 (GLOBE NEWSWIRE) -- Vireo Growth Inc. ("Vireo" or the "Company") (CSE: VREO; OTCQX: VREOF), today reported financial results for its first fiscal quarter ended March 31, 2025. Key financial results are presented below in summary form with supporting commentary and discussion from management of certain key operating metrics which the Company uses to judge its performance. All currency figures referenced herein are denominated in U.S. dollars.

 

Summary of Key Financial Metrics

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

US $ in millions

March 31,

 

 

 

2025

 

 

2024

 

 

Variance

 

 

 

 

 

 

 

 

 

 

GAAP Revenue

$24.5

 

 

$24.1

 

 

1.9%

 

 

GAAP Gross Profit

$12.4

 

 

$12.2

 

 

1.4%

 

 

Gross Profit Margin

50.6%

 

 

50.8%

 

 

-20 bps

 

 

SG&A Expenses

$7.5

 

 

$7.1

 

 

6.0%

 

 

SG&A Expenses (% of Sales)

30.5%

 

 

29.3%

 

 

120 bps

 

 

Operating Income (Loss)

$2.0

 

 

$4.8

 

 

-58.5%

 

 

Operating Income Margin

8.1%

 

 

19.8%

 

 

-1,170 bps

 

 

Adjusted EBITDA

$6.6

 

 

$6.1

 

 

8.5%

 

 

Adjusted EBITDA Margin

26.8%

 

 

25.2%

 

 

160 bps

 

 

 

 

 

 

 

 

 

 

 

Management Commentary

Chief Executive Officer John Mazarakis commented, “First quarter results were in line with our expectations for Vireo’s established markets. We experienced continued growth in Maryland, stable performance in Minnesota, medical sales declines in New York, and the commencement of New York adult use sales from our indoor facility. We remain focused on closing our pending merger transactions, expected to begin during the second quarter.”

Balance Sheet and Liquidity

As of March 31, 2025, total current assets excluding New York assets held for sale were $128.5 million, including cash on hand of $86.3 million. Total current liabilities excluding New York assets held for sale and uncertain tax liabilities were $13.3 million. As of March 31, 2025, the Company had a total of 472,078,412 shares outstanding on the treasury method basis using a share price of $0.45.

Merger Transactions

On March 21, 2025, the Company announced that it filed its Definitive Information Circular with respect to its proposed Merger Transactions. The Circular contains proforma financial information for the combined company as well as 2023 and 2024 audited financial information for each of the various Merger Transaction targets. The Company also announced that it has received requisite shareholder approval in connection with the Merger Transactions after soliciting shareholder approvals via written consent.

The Company has obtained required regulatory approvals for its proposed Utah transactions (“Wholesome Cannabis” and the “Arches” technology platform) and is working toward satisfying all other customary closing conditions of the Merger Transactions, which it expects to meet during the second quarter of 2025.

Conference Call and Webcast Information

Vireo management will host a conference call with research analysts today, May 9, 2025, at 8:30 a.m. ET (7:30 a.m. CT) to discuss its financial results for its first quarter ended March 31, 2025. Interested parties may attend the conference call by dialing 1-888-672-2415 (Toll-Free) (US and Canada) or 1-646-307-1963 (Toll) (International) and referencing conference ID number 3718174.

A live audio webcast of this event will also be available in the Events & Presentations section of the Company’s Investor Relations website and via the following link: https://events.q4inc.com/attendee/968886697.

About Vireo Growth Inc.

Vireo was founded as a pioneer in medical cannabis in 2014 and we are fueled by an entrepreneurial drive that sustains our ongoing commitment to serve and delight our key stakeholders, most notably our customers, our employees, our shareholders, our industry collaborators, and the communities in which we live and operate. We work every day to get better and our team prioritizes 1) empowering and supporting strong local market leaders and 2) strategic, prudent capital and human resource allocation. For more information, please visit www.vireogrowth.com.

Additional Information

Additional information relating to the Company’s first quarter 2025 results will be available on EDGAR and SEDAR later today. Vireo refers to certain non-GAAP financial measures such as Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) and Adjusted EBITDA in circumstances in which the Company believes that doing so provides additional perspective and insights when analyzing the core operating performance of the business. These measures do not have any standardized meaning and may not be comparable to similar measures presented by other issuers. Please see the Supplemental Information and Reconciliation of Non-GAAP Financial Measures at the end of this news release for more detailed information regarding non-GAAP financial measures.

Contact Information

Joe Duxbury
Chief Accounting Officer
[email protected]
(612) 314-8995

Forward-Looking Statement Disclosure

This press release contains “forward-looking information” within the meaning of applicable United States and Canadian securities legislation. To the extent any forward-looking information in this press release constitutes “financial outlooks” within the meaning of applicable United States or Canadian securities laws, this information is being provided as preliminary financial results; the reader is cautioned that this information may not be appropriate for any other purpose and the reader should not place undue reliance on such financial outlooks. Forward-looking information contained in this press release may be identified by the use of words such as “should,” “believe,” “estimate,” “would,” “looking forward,” “may,” “continue,” “expect,” “expected,” “will,” “likely,” “subject to,” “transformation,” and “pending,” variations of such words and phrases, or any statements or clauses containing verbs in any future tense and includes statements regarding the Company’s expected performance in 2025; the Company’s pending merger transactions, including the expected timing of the closing of such mergers; future shareholder returns; the Company’s future access to liquidity; future growth opportunities for the Company; . These statements should not be read as guarantees of future performance or results. Forward-looking information includes both known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company or its subsidiaries to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements or information contained in this press release. Financial outlooks, as with forward-looking information generally, are, without limitation, based on the assumptions and subject to various risks as set out herein and in our Annual Report on Form 10-K filed with the Securities Exchange Commission. Our actual financial position and results of operations may differ materially from management’s current expectations and, as a result, our revenue, EBITDA, Adjusted EBITDA, and cash on hand may differ materially from the values provided in this press release. Forward-looking information is based upon a number of estimates and assumptions of management, believed but not certain to be reasonable, in light of management’s experience and perception of trends, current conditions, and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment, and the availability of licenses, approvals and permits.

Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, the reader should not place undue reliance on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to: risks related to the Company’s pending mergers, including satisfaction of closing conditions and regulatory and shareholder approval; risks related to the timing and content of adult-use legislation in markets where the Company currently operates; current and future market conditions, including the market price of the subordinate voting shares of the Company; risks related to epidemics and pandemics; federal, state, local, and foreign government laws, rules, and regulations, including federal and state laws and regulations in the United States relating to cannabis operations in the United States and any changes to such laws or regulations; operational, regulatory and other risks; execution of business strategy; management of growth; difficulties inherent in forecasting future events; conflicts of interest; risks inherent in an agricultural business; risks inherent in a manufacturing business; liquidity and the ability of the Company to raise additional financing to continue as a going concern; the Company’s ability to meet the demand for flower in Minnesota; risk of failure in the lawsuit with Verano and the cost of that litigation; our ability to dispose of our assets held for sale at an acceptable price or at all; and risk factors set out in the Company's Form 10-K for the year ended December 31, 2024, which is available on EDGAR with the U.S. Securities and Exchange Commission and filed with the Canadian securities regulators and available under the Company's profile on SEDAR at www.sedar.com.

The statements in this press release are made as of the date of this release. Except as required by law, we undertake no obligation to update any forward-looking statements or forward-looking information to reflect events or circumstances after the date of such statements.

Supplemental Information

The financial information reported in this news release is based on unaudited financial statements for the first quarter ended March 31, 2025, and March 31, 2024. All financial information contained in this news release is qualified in its entirety with reference to such financial statements. To the extent that the financial information contained in this news release is inconsistent with the information contained in the Company’s audited financial statements, the financial information contained in this news release shall be deemed to be modified or superseded by the Company’s audited financial statements. The making of a modifying or superseding statement shall not be deemed an admission for any purposes that the modified or superseded statement, when made, constituted a misrepresentation for purposes of applicable securities laws.

 

 

 

 

 

 

 

 

 

 

 

VIREO GROWTH INC.

 

 

 

 

 

 

 

 

 

CONSOLIDATED BALANCE SHEETS AS OF MARCH 31, 2025 AND DECEMBER 31, 2024

 

 

 

 

 

 

 

 

 

(Amounts Expressed in United States Dollars, Unaudited and Condensed)

 

 

 

 

 

 

 

 

 

 

 

March 31,

    

December 31, 

 

 

 

 

 

2025

 

2024

 

 

 

Assets

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash

 

$

86,260,997

 

$

91,604,970

 

 

 

Accounts receivable, net of credit losses of $259,011 and $254,961, respectively

 

 

3,983,466

 

 

4,590,351

 

 

 

Income tax receivable

 

 

11,367,067

 

 

12,027,472

 

 

 

Inventory

 

 

23,343,300

 

 

21,666,364

 

 

 

Prepayments and other current assets

 

 

1,785,664

 

 

1,650,977

 

 

 

Warrants held

 

 

1,751,906

 

 

2,270,964

 

 

 

Assets Held for Sale

 

 

99,941,960

 

 

96,560,052

 

 

 

Total current assets

 

 

228,434,360

 

 

230,371,150

 

 

 

Property and equipment, net

 

 

32,836,175

 

 

32,311,762

 

 

 

Operating lease, right-of-use asset

 

 

7,660,568

 

 

7,859,434

 

 

 

Intangible assets, net

 

 

7,694,517

 

 

7,899,328

 

 

 

Deposits

 

 

421,244

 

 

421,244

 

 

 

Total assets

 

$

277,046,864

 

$

278,862,918

 

 

 

Liabilities

 

 

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

 

 

 

Accounts payable and accrued liabilities

 

$

12,197,467

 

$

10,456,036

 

 

 

Long-Term debt, current portion

 

 

—

 

 

900,000

 

 

 

Right of use liability

 

 

1,148,991

 

 

1,400,015

 

 

 

Uncertain tax liability

 

 

34,959,000

 

 

33,324,000

 

 

 

Liabilities held for sale

 

 

89,351,157

 

 

89,387,203

 

 

 

Total current liabilities

 

 

137,656,614

 

 

135,467,254

 

 

 

Right-of-use liability

 

 

16,437,288

 

 

16,494,439

 

 

 

Other long-term liabilities

 

 

37,278

 

 

37,278

 

 

 

Convertible debt, net

 

 

9,874,521

 

 

9,862,378

 

 

 

Long-Term debt, net

 

 

62,603,583

 

 

61,438,046

 

 

 

Total liabilities

 

$

226,609,284

 

$

223,299,395

 

 

 

Stockholders’ deficiency

 

 

 

 

 

 

 

 

 

Subordinate Voting Shares ($- par value, unlimited shares authorized; 339,475,288 shares issued and outstanding at March 31, 2025 and 337,512,681 at December 31, 2024)

 

 

—

 

 

—

 

 

 

Multiple Voting Shares ($- par value, unlimited shares authorized; 278,170 shares issued and outstanding at March 31, 2025 and 285,371 at December 31, 2024)

 

 

—

 

 

—

 

 

 

Additional paid in capital

 

 

288,381,930

 

 

286,999,084

 

 

 

Accumulated deficit

 

 

(237,944,351

)

 

(231,435,561

)

 

 

Total stockholders' equity (deficiency)

 

$

50,437,579

 

$

55,563,523

 

 

 

Total liabilities and stockholders' deficiency

 

$

277,046,864

 

$

278,862,918

 

 

 

 

 

 

 

 

 

 

 

 


 

 

 

 

 

 

 

 

VIREO GROWTH INC.

 

 

 

 

 

 

 

CONSOLIDATED STATEMENTS OF OPERATIONS

 

 

 

 

THREE MONTHS ENDED MARCH 31, 2025 AND 2024

 

 

 

 

(Amounts Expressed in United States Dollars, Unaudited and Condensed)

 

 

 

 

 

    

Three Months Ended

 

 

 

March 31,

 

 

    

2025

 

    

2024

 

 

Revenue

 

$

24,540,641

 

 

$

24,087,315

 

 

Cost of sales

 

 

 

 

 

 

 

Product costs

 

 

11,695,329

 

 

 

12,146,888

 

 

Inventory valuation adjustments

 

 

433,000

 

 

 

(304,000

)

 

Gross profit

 

 

12,412,312

 

 

 

12,244,427

 

 

Operating expenses:

 

 

 

 

 

 

 

Selling, general and administrative expenses

 

 

7,473,943

 

 

 

7,051,613

 

 

Transaction related expenses

 

 

1,244,696

 

 

 

—

 

 

Stock-based compensation expenses

 

 

1,460,850

 

 

 

179,789

 

 

Depreciation

 

 

77,102

 

 

 

73,547

 

 

Amortization

 

 

180,032

 

 

 

180,034

 

 

Total operating expenses

 

 

10,436,623

 

 

 

7,484,983

 

 

 

 

 

 

 

 

 

 

Gain (loss) from operations

 

 

1,975,689

 

 

 

4,759,444

 

 

 

 

 

 

 

 

 

 

Other income (expense):

 

 

 

 

 

 

 

Interest expenses, net

 

 

(7,599,517

)

 

 

(8,722,637

)

 

Impairment of long-lived assets

 

 

—

 

 

 

—

 

 

Gain (loss) on disposal of assets

 

 

—

 

 

 

(120,856

)

 

Other income (expenses)

 

 

790,038

 

 

 

1,317,589

 

 

Other income (expenses), net

 

 

(6,809,479

)

 

 

(7,525,904

)

 

 

 

 

 

 

 

 

 

Loss before income taxes

 

 

(4,833,790

)

 

 

(2,766,460

)

 

 

 

 

 

 

 

 

 

Current income tax expenses

 

 

(1,675,000

)

 

 

(3,945,000

)

 

Deferred income tax recoveries

 

 

—

 

 

 

—

 

 

Net loss and comprehensive loss

 

 

(6,508,790

)

 

 

(6,711,460

)

 

Net loss per share - basic and diluted

 

$

(0.02

)

 

$

(0.05

)

 

Weighted average shares used in computation of net loss per share - basic & diluted

 

 

366,800,177

 

 

 

143,126,330

 

 

 

 

 

 

 

 

 

 

 

 


 

 

 

 

 

 

 

 

VIREO GROWTH INC.

 

 

 

 

 

 

 

CONSOLIDATED STATEMENTS OF CASH FLOWS

 

 

 

 

 

 

 

THREE MONTHS ENDED MARCH 31, 2025 AND 2024

 

 

 

 

 

 

 

(Amounts Expressed in United States Dollars, Unaudited and Condensed)

 

 

 

 

 

 

 

 

 

MARCH 31,

 

 

    

2025

 

    

2024

 

 

CASH FLOWS FROM OPERATING ACTIVITIES

 

 

 

 

 

 

 

Net loss

 

$

(6,508,790

)

 

$

(6,711,460

)

 

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

Inventory valuation adjustments

 

 

433,000

 

 

 

(304,000

)

 

Depreciation

 

 

77,102

 

 

 

73,547

 

 

Depreciation capitalized into inventory

 

 

545,262

 

 

 

560,180

 

 

Non-cash operating lease expense

 

 

121,038

 

 

 

103,564

 

 

Amortization of intangible assets

 

 

180,032

 

 

 

180,034

 

 

Amortization of intangible assets capitalized into inventory

 

 

24,778

 

 

 

24,778

 

 

Stock-based payments

 

 

1,321,220

 

 

 

179,789

 

 

Warrants held

 

 

519,058

 

 

 

(1,327,879

)

 

Interest Expense

 

 

1,213,681

 

 

 

2,015,889

 

 

Accretion

 

 

50,284

 

 

 

52,815

 

 

Loss (gain) on disposal of assets

 

 

—

 

 

 

120,856

 

 

Change in operating assets and liabilities:

 

 

 

 

 

 

Accounts Receivable

 

 

606,886

 

 

 

348,817

 

 

Prepaid expenses

 

 

(134,688

)

 

 

290,106

 

 

Inventory

 

 

(2,032,109

)

 

 

299,252

 

 

Income taxes

 

 

660,406

 

 

 

175,203

 

 

Uncertain tax position liabilities

 

 

1,635,000

 

 

 

3,760,000

 

 

Accounts payable and accrued liabilities

 

 

1,818,743

 

 

 

174,340

 

 

Changes in operating lease liabilities

 

 

(358,459

)

 

 

(168,746

)

 

Change in assets and liabilities held for sale

 

 

(3,495,266

)

 

 

(1,037,417

)

 

Net cash provided by (used in) operating activities

 

$

(3,322,822

)

 

$

(1,190,332

)

 

 

 

 

 

 

 

 

 

CASH FLOWS FROM INVESTING ACTIVITIES:

 

 

 

 

 

 

 

PP&E Additions

 

$

(1,146,777

)

 

$

(899,264

)

 

Deposits

 

 

—

 

 

 

(150,100

)

 

Net cash provided by (used in) investing activities

 

$

(1,146,777

)

 

$

(1,049,364

)

 

 

 

 

 

 

 

 

 

CASH FLOWS FROM FINANCING ACTIVITIES

 

 

 

 

 

 

 

Proceeds from warrant exercises

 

 

38,516

 

 

 

—

 

 

Proceeds from option exercises

 

 

23,110

 

 

 

—

 

 

Debt principal payments

 

 

(936,000

)

 

 

(1,050,000

)

 

Lease principal payments

 

 

—

 

 

 

(71,066

)

 

Net cash provided by (used in) financing activities

 

$

(874,374

)

 

$

(1,121,066

)

 

 

 

 

 

 

 

 

 

Net change in cash

 

$

(5,343,973

)

 

$

(3,360,762

)

 

 

 

 

 

 

 

 

 

Cash, beginning of year

 

$

91,604,970

 

 

$

15,964,665

 

 

 

 

 

 

 

 

 

 

Cash, end of year

 

$

86,260,997

 

 

$

12,603,903

 

 

 

 

 

 

 

 

 

 


 

VIREO GROWTH INC.

STATE-BY-STATE REVENUE PERFORMANCE

THREE MONTHS ENDED MARCH 31, 2025 AND 2024

 

 

 

Three Months Ended

 

 

 

 

 

 

 

 

March 31,

 

 

 

 

 

 

 

 

2025

 

2024

 

$ Change

 

% Change

 

Retail:

 

 

 

 

 

 

 

 

 

 

 

 

MN

 

$

11,209,204

 

$

10,977,089

 

$

232,115

 

 

2

 

%

NY

 

 

1,205,045

 

 

1,821,269

 

 

(616,224

)

 

(34

)

%

MD

 

 

6,819,392

 

 

6,801,082

 

 

18,310

 

 

0

 

%

Total Retail

 

$

19,233,641

 

$

19,599,440

 

$

(365,799

)

 

(2

)

%

 

 

 

 

 

 

 

 

 

 

 

 

 

Wholesale:

 

 

 

 

 

 

 

 

 

 

 

 

MD

 

 

4,089,238

 

 

3,353,661

 

 

735,577

 

 

22

 

%

NY

 

 

936,351

 

 

1,134,214

 

 

(197,863

)

 

(17

)

%

MN

 

 

281,411

 

 

—

 

 

281,411

 

 

100

 

%

Total Wholesale

 

$

5,307,000

 

$

4,487,875

 

$

819,125

 

 

18

 

%

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Revenue

 

$

24,540,641

 

$

24,087,315

 

$

453,326

 

 

2

 

%

 

 

 

 

 

 

 

 

 

 

 

 

 

Reconciliation of Non-GAAP Financial Measures

Vireo management occasionally elects to provide certain non-GAAP financial measures such as Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) and Adjusted EBITDA. EBITDA and Adjusted EBITDA are a non-GAAP measure and does not have a standardized definition under GAAP. The following information provides reconciliations of the supplemental non-GAAP financial measures, presented herein to the most directly comparable financial measures calculated and presented in accordance with GAAP. The Company has provided the non-GAAP financial measures, which are not calculated or presented in accordance with GAAP, as supplemental information and in addition to the financial measures that are calculated and presented in accordance with GAAP. These supplemental non-GAAP financial measures should not be considered superior to, as a substitute for or as an alternative to, and should be considered in conjunction with, the GAAP financial measures presented.

 

 

 

 

 

 

 

 

Reconciliation of Net Loss to EBITDA and Adjusted EBITDA

 

 

 

 

 

 

 

(Amounts Expressed in United States Dollars, Unaudited and Condensed)

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

 

March 31,

 

 

 

2025

 

 

2024

 

 

Net income (loss)

 

$

(6,508,790

)

 

$

(6,711,460

)

 

Interest expense, net

 

 

7,599,517

 

 

 

8,722,637

 

 

Income taxes

 

 

1,675,000

 

 

 

3,945,000

 

 

Depreciation & Amortization

 

 

257,134

 

 

 

253,581

 

 

Depreciation and amortization included in cost of goods sold

 

 

570,040

 

 

 

584,958

 

 

EBITDA (non-GAAP)

 

$

3,592,901

 

 

$

6,794,716

 

 

Inventory adjustment

 

$

433,000

 

 

$

304,000

 

 

Grown Rogue termination fee included in cost of goods sold

 

 

266,667

 

 

 

—

 

 

Stock-based compensation

 

 

1,460,850

 

 

 

179,789

 

 

Transaction related expenses

 

 

1,244,696

 

 

 

—

 

 

Other income

 

 

(790,038

)

 

 

(1,327,879

)

 

Severance expense

 

 

379,916

 

 

 

—

 

 

Loss on disposal of assets

 

 

—

 

 

 

120,856

 

 

Adjusted EBITDA (non-GAAP)

 

$

6,587,992

 

 

$

6,071,482